Two blogs on why biosimilar pricing doesn't work, and why it won't work, and why we should treat the first biosimilar as a strongly regulated monopoly when it's patent expires. Health Affairs, Blogs, April 2019.
https://www.healthaffairs.org/do/10.1377/hblog20190405.396631/full/
https://www.healthaffairs.org/do/10.1377/hblog20190405.839549/full/
Herper and Silverman discuss the plan in STAT
https://www.statnews.com/2019/04/15/peter-bachs-latest-crazy-idea-give-up-on-biosimilars-regulate-drug-prices-instead/
##
In 2017, Bach and Trusheim suggested it was cheapest for US Govt to buy Gilead.
https://www.forbes.com/sites/sciencebiz/2017/01/17/the-u-s-government-should-buy-gilead-for-156-billion-to-save-money-on-hepatitis-c
##
For earlier work by Trusheim, see Berndt & Trusheim, 2017, article on precision medicine and game theory, here or here. (Quinn has ms. PDF). This is a chapter in a 2019 book, "Economic Dimensions of Personalized and Precision Medicine," Univ Chicago, here. Etextbook, $123 here. Release date 4/22/2019.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.